Skip to main content
Premium Trial:

Request an Annual Quote

Sistemic to Apply miRNA Platform to Standardize Stem Cell Manufacturing


Sistemic, a microRNA services firm based in Glasgow, UK, has signed an agreement with Roslin Cells that aims to standardize the manufacture of stem cells for use in cell therapy and drug development screening.

Under the terms of the agreement, Roslin will use Sistemic's SistemQC service, which applies miRNA profiling to monitor stem cell identity, safety, and differentiation staging.

Aidan Courtney, CEO of Roslin, said in a statement that the characterization of both primary tissue and of cells in culture is "fundamental to our operation" and "underpins our ability to produce the highest possible quality of cells for use in cell therapies and as research tools."

He added that the collaboration with Sistemic "will enable us to improve our production processes and deliver more extensive and valuable data to those using our cells.”